A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy

CONCLUSIONS: The Ibrutinib-Obinutuzumab combo has the highest risk of infection, atrial fibrillation and myelosuppression, the Ibrutinib-Lenalidomide combo has the highest risk of pyrexia. However, the Ibrutinib-Venetoclax combo has a lower risk of hemorrhage than monotherapy.PMID:38456691 | DOI:10.1080/14740338.2024.2327507
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: Source Type: research